The Novelty of an Optical Isomer is not Negated by the Prior Art Disclosure of its Racemate
In UCB, Inc. v. Accord Healthcare, Inc., [2016-2610, 2016-2683, 2016-2685, 2016-2698, 2016-2710, 2017-1001] (May 23 2018), the Federal Circuit affirmed the district court’s determination that UCB’s patents on lacosamide, an anti-epileptic drug, were not invalid for obviousness-type double patenting, obviousness, and anticipation. … Continue reading The Novelty of an Optical Isomer is not Negated by the Prior Art Disclosure of its Racemate
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed